Sanofi Consumer Health Zantac Product Recall (2019-10-18)Health ProductsOct 18th, 2019 @ 12:00 AM
Basic Details
Issue: Product Safety
Category: Drugs
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
Alert type: Drug Recall
Summary
Product
Zantac 75 mg Tablet;
Products
| Lot or serial number | Companies | Brand name | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|---|---|---|---|---|
| All lots |
| B. Zantac 150 mg Tablet | DIN 02277301 | Tablet | Ranitidine 150 mg |
| All lots |
| A. Zantac 75 mg Tablet | DIN 02230287 | Tablet | Ranitidine 75 mg |
Introduction
- Zantac 75 mg Tablet;
- Zantac 150 mg Tablet
Reason
Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).
Depth of distribution
Wholesalers, Healthcare Establishments, Retailers
Related alerts
Additional ranitidine products recalled, including Zantac; request to stop distribution remains in place while Health Canada continues to assess NDMA
2019-09-25 | Drugs
Type of communication: Advisory
2019-09-25 | Drugs
Type of communication: Advisory
Recall Monitor
Information presented from Recalls and Safety Alerts dataset, provided by the Government of Canada through the Open Government initiative and is subject to the Open Government License.
You can access this data free of charge via Recall Monitor, or through the Healthy Canadians website.
Get personalized SMS or Email notifications about recall alerts that matter by subscribing to Recall Monitor.
Recall Monitor is not endorsed by, or is an official product of the Government of Canada.
Made with in Vancouver, BC
© Mad Filaments Software Inc.